WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021.
“Atopic dermatitis is a chronic inflammatory skin condition that can have serious impacts on patients’ quality of life,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “We are pleased to present data that highlight the potential of ruxolitinib cream as an effective topical treatment for patients with AD at the SID Virtual Meeting and are thankful for the SID’s efforts in hosting this event virtually for the second year to promote ongoing scientific exchange that could lead to improved outcomes for patients.”
Key abstracts from Incyte-sponsored studies include:
Effects of Ruxolitinib Cream in Patients with Atopic Dermatitis with Head and/or Neck Involvement (Abstract #311. Patient Population Research)
Ruxolitinib Cream Rapidly Decreases Skin Pain in Atopic Dermatitis (Abstract #325. Patient Population Research)
Itch-Free State in Patients with Atopic Dermatitis Treated with Ruxolitinib Cream (Abstract #313. Patient Population Research)
Efficacy of Ruxolitinib Cream in Adults and Adolescents with Atopic Comorbidities (Abstract #329. Patient Population Research)
Atopic Dermatitis: Patient Characteristics and Patient-Reported Outcomes on Topical Therapy (Abstract #333. Patient Population Research)
All presentations are available on-demand through May 31, 2021. Session details and listings of all presentations are available in the SID meeting program: https://www.sidannualmeeting.org/information/meeting-program-attendee-user-guide/.
About Ruxolitinib Cream
Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.
Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development program of ruxolitinib cream, its , atopic dermatitis and other dermatology programs generally, and whether or when ruxolitinib cream will be approved or commercially available for use in humans in the U.S. or elsewhere, its presentation plans for the upcoming SID meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.